All the tests offered by Prenato are free of risk for the mother and the fetus. This test can be done as early as the 10th week of pregnancy through a simple and unique blood sample.
Superior quality, precocity, and competitiveness
Results before the end of the 12th week
This screening test is done by taking a simple and unique blood sample, and is based on the serum markers: hormones produced by the fetus or the placenta, passing into the mother’s blood flow during pregnancy. After the blood sample is taken, between the 11th and 13th week of pregnancy, the analysis allows us to assess the risk of the main trisomies (21, 18, …) for the fetus. The risk calculation is made by combining the age of the patient, the nuchal translucency measure taken at the first semester, and the 4-hormone analysis during the first semester. Prenato has introduced the first quadtest in Quebec: by multiplying the number of hormones analyzed in the first test, we raise the efficiency of the Premium Prenato Screening.
Exclusive to Prenato, the hormone analysis is also available for twin pregnancies, recommended by Canadian practical guides since September 2017.
99.9% reliable (for main trisomy)
Results available before the end of the 11th week
Earliest test with this level of reliability on the market
Noninvasive prenatal testing (NIPT)is a newer, more advanced screening option which uses cell-free DNA in a pregnant mother’s blood to test for certain chromosome conditions in her pregnancy, without the risks associated with invasive procedures, such as amniocentesis or chorionic villus sampling (CVS).
This test can be performed as early as 10 weeks’ gestation, with results available in 3-5 business days
Exclusively offered at Prenato
The only test available in North America that offers an all-chromosome option that provides information about trisomies for all chromosomes as well as clinically significant microdeletions, giving you a broader range of information, with results available as early as 10 weeks’ gestation.
This test, which uses cell-free DNA in a pregnant mother’s blood, is performed from a single tube of mother’s blood, drawn as early as 10 weeks in the pregnancy, provides information about trisomies for ALL chromosomes as well as clinically significant microdeletions, giving you a broader range of information. Test allows you more insights with an expanded elective panel that includes all autosomal trisomies as well as clinically significant microdeletions such as 22q11.2 deletion syndrome (DiGeorge syndrome, velocardiolfacial syndrome), 1p36 deletion syndrome, Angelman syndrome (15q11.2 microdeletion), Prader-Willi syndrome (15q11.2 microdeletion), Cri du chat syndrome (5p- syndrome), Wolf-Hirschhorn syndrome (4p- syndrome).
Test results will be returned to your health care provider within 3-5 business days.
This test can also help patients better understand the loss of a pregnancy, such as a miscarriage or stillbirth.